Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor
The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.
Advanced Solid Tumor
DRUG: Camrelizumab/sintilimab+ Standard chemotherapy|DRUG: Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）|DRUG: Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy
PFS, Baseline to measured date of progression or death from any cause, evaluated in 24 months since the treatment began
ORR, Baseline to measured stable disease, tumor assessment every 6 weeks since the treatment began，up to 24 months|DCR, Baseline to measured progressive disease, tumor assessment every 6 weeks since the treatment began，up to 24 months|OS, Overall survival, the first day of treatment to death or last survival confirm date,up to 24 months|Adverse events, Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. The number of Participants with adverse events will be recorded at each treatment visit., up to 24 weeks
The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.